NEW YORK (GenomeWeb) – Signal Genetics reported on Wednesday a 43 percent drop in its second quarter revenues on a sharp decrease in test orders. 

The Carlsbad, California-based molecular diagnostics firm said that for the three months ended June 30, it recorded $734,000 in revenues, down from $1.3 million in the year-ago quarter. Test orders retreated 24 percent year over year to 770 in Q2 2015, resulting from a decrease in the number of tests billed for research and clinical patients at the University of Arkansas Medical Sciences, Signal's primary customer. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul
11
Sponsored by
Genomenon

This webinar will discuss an approach for automating variant classification based on the American College of Medical Genetics and Genomics guidelines.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.